A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.

Abstract

Regorafenib is an oral multikinase inhibitor targeting angiogenesis, oncogenesis, and cancer proliferation/metastasis. This study evaluated the efficacy of regorafenib in refractory biliary tract cancer (BTC) in a multi-institutional phase 2 study. Patients with BTC who progressed on at least 1 line of systemic therapy received regorafenib at 160mg daily for 21days on and 7days off. The primary endpoint was 6-month overall survival (OS), and the secondary endpoints were median OS, progression-free survival (PFS), and objective response rates. Pretreatment plasma was collected for cytokine evaluation. A total of 39 patients were enrolled, and 33 were evaluable for efficacy. The median PFS and OS were 3.7 and 5.4months, respectively, with survival rates of 46.2% at 6months, 35.9% at 12months, and 25.6% at 18months for the intention-to-treat population. For the 33 evaluable patients who received regorafenib for at least 3weeks, the median PFS and OS were 3.9 and 6.7months, respectively, with survival rates of 51.5% at 6months, 39.4% at 12months, and 27.3% at 18months. The objective response rate was 9.1%, and the disease control rate was 63.6%. Twenty-eight patients (71.8%) experienced grade 3/4 adverse events. Among the 23 cytokines analyzed, elevated baseline vascular endothelial growth factor D (VEGF-D) was associated with shorter PFS, whereas elevated baseline interleukin 6 (IL-6) and glycoprotein 130 (GP130) were associated with shorter OS. Regorafenib demonstrated modest clinical efficacy in heavily pretreated patients with BTC. Further exploration of biomarkers is warranted to identify a group of patients with BTC who may benefit from regorafenib.